Holen Sie sich die Stockscreener-App
0.7274
5.43%
-0.0418
Handel nachbörslich:
.72
-0.0074
-1.02%
Schlusskurs vom Vortag:
$0.7692
Offen:
$0.77
24-Stunden-Volumen:
2.42M
Relative Volume:
0.52
Marktkapitalisierung:
$211.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-2.6941
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
-6.74%
1M Leistung:
-9.64%
6M Leistung:
-48.23%
1J Leistung:
+35.73%
1-Tages-Spanne:
$0.7252
$0.7738
1-Wochen-Bereich:
$0.705
$0.7894
52-Wochen-Spanne:
$0.495
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.7274 | 211.91M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Files Secondary Stock Shelf -January 31, 2025 at 04:44 pm EST - Marketscreener.com
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen’s OCU-500 inhaled mucosal vaccine for COVID-19 gains IND clearance - BioWorld Online
Ocugen, Inc. Announces Investigational New Drug Application - GlobeNewswire
FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials - StockTitan
Ocugen Stock: Positioned for Growth Amid Biopharma Innovation - The Africa Logistics
Ocugen's (OCGN) Buy Rating Reiterated at Chardan Capital - MarketBeat
Ocugen's (OCGN) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Lawsuits Filed Against OCGN, CRMD and ARDXJakubowitz Law Pursues Shareholders Claims - AccessWire
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? - MSN
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa - MSN
Breakthrough in Sight? Ocugen's OCU200 Targets Vision Loss for Millions in New Clinical Trial - MyChesCo
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment - MSN
Breakthrough in Vision: Ocugen's OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa - MyChesCo
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Ocugen
Ocugen, Inc. Announces First Patient Dosed in Phase 1 - GlobeNewswire
Ocugen Launches Phase 1 Trial for Novel Eye Disease Treatment OCU200 in Diabetic Patients - StockTitan
Long-term potential revealed for novel modifier gene therapy - Marketscreener.com
Ocugen's (OCGN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - Ocugen
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple - GlobeNewswire
Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - StockTitan
Earnings call transcript: Ocugen Q3 2024 highlights clinical progress By Investing.com - Investing.com Canada
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Earnings call transcript: Ocugen Q3 2024 highlights clinical progress - Investing.com
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MSN
Ocugen’s Gene Therapy Trial for Dry AMD Advances - MSN
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
State Street Corp Increases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - MarketBeat
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Ocugen Inc. stock rises Friday, still underperforms market - MarketWatch
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Data and Safety Monitoring Board Reviews Interim Safety - GlobeNewswire
Ocugen's Eye Treatment Shows Promising Safety Data in Phase 1/2 Trial for Macular Degeneration - StockTitan
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):